MARKET WIREYahoo! Finance Canada • 10h ago
Baxter International Inc. (BAX) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Baxter International Inc. (BAX) market action, institutional positioning, and fundamental catalysts.
Why BAX Stock dropped -2.13% Today — RQD Quant Desk Flash
$23.00 -2.13% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $22.87
Baxter International Inc. (BAX) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $12.15B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BAX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Baxter International Inc. (NYSE: BAX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $23.00 (-2.13% 1D, market cap $12.15B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, BAX ranks #278 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BAX compare to PEN and GMED in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), BAX carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of 30.1%, and ROIC of -2.4%. By comparison, PEN (Penumbra Inc.) holds a D+ grade (57/100 RQD, P/E 71.4x, ROIC 10.6%, cap $12.68B) and GMED (Globus Medical Inc.) posts a B grade (72/100 RQD, P/E 20.7x, ROIC 8.7%, cap $11.13B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BAX?
▼
Per BAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000010456), Baxter International Inc. generated $11.24B in revenue (+5.7% YoY), -$957.0M in net income, and $339.0M in free cash flow against $20.05B in total assets and $6.28B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $22.87 (-0.57%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 3% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-3.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BAX)Realized 20D OHLCV Swing Band: ±8.5%
Deterministic 5-Pillar Attribution (51/100 Composite)
🔍 WHY BAX SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+12/20 pts (24% of score)
SEC Form 4 / 13F Thermometer: 60% Net Buy • Cannibal Buyback (-1.24% YoY Shares)
▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (20% of score)
SEC XBRL FY 2025 (10-K): 3% FCF Margin ($339.0M FCF) & 30.1% Gross Margin
▼ #1 Drag / Risk Factor: Macro Regime Fit9/20 pts (-11 pt drag)
Macro rate sensitivity & RSI-14 (42.3) create a -11 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$24.89-1.5% Next Q
59
Q2 (-2Q)Grade C$24.51+1.7% Next Q
56
Q3 (-1Q)Grade C-$24.92-7.7% Next Q
54
CurrentGrade D$23.00-1.3% Hist 90D α
51
Trajectory: C (59) → D (51)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BAX Turnaround Squeeze
While BAX currently carries a cautious 51/100 (D) rating due to Macro Regime Fit (9/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.47) and Max Pain ($24.15) forces dealer call-delta covering toward $31.50.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-1.24% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BAX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BAX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BAX Stock dropped -2.13% Today — RQD Quant Desk Flash
Baxter International Inc. (BAX) dropped -2.13% to $23.00, trading at 51% of its 52-week range ($15.73 – $30). Stretched risk/reward at current multiples (-2% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 51% of its 52-week range ($15.73 – $30) with RSI-14 at 42.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8.5% around $23.00 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 30.1% gross margin and $339.0M annual free cash flow.
Live BAX Headlines & Catalysts
MARKET WIRESeeking Alpha • 13h ago
Baxter International: The Vantive Transition Complicates Margin RecoverySeeking Alpha report covering Baxter International Inc. (BAX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 16h ago
Why Baxter (BAX) Stock Is Down TodayTradingView report covering Baxter International Inc. (BAX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 19h ago
Baxter (BAX) Stock May Be 30% Undervalued On Cash FlowYahoo Finance report covering Baxter International Inc. (BAX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREChartMill • 22h ago
Baxter International Inc (NYSE:BAX) Breakout Setup Shows Technical StrengthChartMill report covering Baxter International Inc. (BAX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
Why Is Baxter Stock Trading Lower on Thursday?Benzinga report covering Baxter International Inc. (BAX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREmarketscreener.com • 1d ago
Earnings Flash (BAX) Baxter International Inc. Posts Q3 Adjusted EPS $0.58 per Share, vs. FactSet Est of $0.52marketscreener.com report covering Baxter International Inc. (BAX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Baxter (BAX) Stock Price Slips Despite Q3 Results Backing TurnaroundSimply Wall St report covering Baxter International Inc. (BAX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 3d ago
JP Morgan Maintains Neutral on Baxter International, Lowers Price Target to $25JP Morgan analyst Robbie Marcus maintains Baxter International (NYSE:BAX) with a Neutral and lowers the price target from $26 to $25.
CATALYSTYahoo • 3d ago
BAX Q3 deep dive: cost actions and product changes shape outlook amid market cautionHealthcare company Baxter International (NYSE:BAX) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 5% year on year to $2.98 billion. Its non-GAAP profit of $0.58 per share was 11.9% abo
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BAX)
- ✓Walkthrough of BAX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BAX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +38.39%🛡️ HOLDING TREND SUPPORT
2026-11-02O $25.46H $25.46L $23.00C $23.00VOL 15.67M
RES: $25.92SUP: $22.53SMA50: $24.47SMA200: $21.37
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BAX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
11.2%/yr Implied 5Y Growth
vs. +5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on BAX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BAX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BAX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BAX)
Health Care Rank #278 of 1016
⚔️ PEN vs BAX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BAX vs. PEN, GMED, PODD, SOLV)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Baxter International Inc. (BAX) ranks #278 by composite RQD confidence (51/100, grade D) and #92 by equity capitalization ($12.15B). Within this direct 5-issuer industry benchmark cohort, SOLV leads on earnings valuation at 9.1x trailing P/E, while PODD leads on capital efficiency and profitability with 20.4% ROIC and 71.6% gross margin. PODD currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with BAX at 51/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BAX
ACTIVE
Baxter International Inc. | D | 51/100 | — | 30.1% | -2.4% | -2.13% | $12.15B | Benchmark Subject |
| PEN Penumbra Inc. | D+ | 57/100 | 71.4x | 67.1% | 10.6% | -0.94% | $12.68B | /pen-vs-bax → |
| GMED Globus Medical Inc. | B | 72/100 | 20.7x | 67.4% | 8.7% | -5.86% | $11.13B | /gmed-vs-bax → |
| PODD Insulet Corporation | B | 73/100 | 42.8x | 71.6% | 20.4% | -1.85% | $10.58B | /podd-vs-bax → |
| SOLV Solventum Corporation | D | 45/100 | 9.1x | 53.5% | 18.7% | -2.67% | $14.22B | /solv-vs-bax → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000010456In its most recent audited fiscal period (FY2025, filed 2025-12-31), Baxter International Inc. (BAX) reported GAAP revenue of $11.24B (+5.7% vs. FY2024 revenue of $10.64B , and +8.5% cumulative change since FY2023) , GAAP net income of -$957.0M, operating cash flow of $845.0M, and free cash flow of $339.0M (-37.3% YoY). On the balance sheet, BAX closed FY2025 with $20.05B in total assets against $6.28B in total debt (Altman Z-Score: 2.22, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $11.24B | -$957.0M | $845.0M | $339.0M | $20.05B | $6.28B |
| FY2024 (FY) | 2024-12-31 | $10.64B | -$649.0M | $1.02B | $540.4M | $25.78B | $8.44B |
| FY2023 (FY) | 2023-12-31 | $10.36B | $2.66B | $1.73B | $1.26B | $12.43B | $2.91B |
3. BAX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Baxter International Inc. (NYSE: BAX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $23.00 (-2.13% 1D, market cap $12.15B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, BAX ranks #278 in composite RQD confidence.
How does BAX compare to PEN and GMED in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), BAX carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of 30.1%, and ROIC of -2.4%. By comparison, PEN (Penumbra Inc.) holds a D+ grade (57/100 RQD, P/E 71.4x, ROIC 10.6%, cap $12.68B) and GMED (Globus Medical Inc.) posts a B grade (72/100 RQD, P/E 20.7x, ROIC 8.7%, cap $11.13B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BAX?
Per BAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000010456), Baxter International Inc. generated $11.24B in revenue (+5.7% YoY), -$957.0M in net income, and $339.0M in free cash flow against $20.05B in total assets and $6.28B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BAX trading relative to its 50-day, 200-day, and 52-week technical levels?
BAX last traded at $23.00 (-2.13% on volume of 11,817,730 shares), positioning the stock -6.01% below its 50-day simple moving average ($24.47) and +7.63% above its 200-day simple moving average ($21.37). Across its 52-week range of $15.73 to $30.00, BAX sits at the 50.9% percentile with a 14-day RSI of 42.3 (NEUTRAL RANGE) and an implied next-earnings move of ±8.5% ($21.04 to $24.96).
BAX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BAX stock moving today?
Why BAX Stock dropped -2.13% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-2% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 51/100 (D)
✓ STAGE-C NUMBER FIREWALL VERIFIED
BAX — Baxter International Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:15:37Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, BAX scores 51 out of 100, grade D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:
- Fundamental Cash Engine: 10 / 20. Per the RQD rating and market data, ROIC is -2.4% and FCF yield is 2.79%. A negative ROIC means the business is not currently earning a return above its capital base, which weighs on the cash-engine case even though FCF yield is positive.
- Whale 13F Flow: 10 / 20. The RQD rating cites institutional accumulation and options positioning as the basis for this pillar. Specific 13F holder data is not available in source data, so the score cannot be traced to named holders here.
- Insider Conviction: 12 / 20. The RQD rating references SEC Form 4 and Congressional PTR cluster flow. Individual transactions are not available in source data.
- Macro Regime Fit: 9 / 20. Per the RQD rating, beta is 0.95 and sector sensitivity is the stated driver. A beta near 1.0 implies moves roughly in line with the broader market, but the score reflects a weak fit with the current regime as assessed by the rating.
- Forensic Balance Sheet: 10 / 20. Per the RQD rating, Altman Z is 2.22, Piotroski F is 6/9, and Debt/Equity is 0.96. These are middling readings: the Z-score and F-score do not signal distress or strength decisively, and leverage is near 1x equity.
Taken together, the rating points to weak cash generation on a return basis, mixed institutional and insider signals whose detail is not available, and a balance sheet that is neither a clear strength nor a clear failure. For a prospective investor, the upside case rests on the 2.79% FCF yield and the 18x forward P/E relative to trailing losses (EPS TTM -1.85), while the downside case rests on negative ROIC, negative operating and net margins, and a rating that flags distribution. The valuation tradeoff is that a low forward multiple only helps if forward earnings recover as the rating's negative pillars imply they may not.
Business
Baxter International Inc. is a NYSE-listed issuer in the Health Care sector, Medical/Dental Instruments industry, per the company profile. The profile identifies the company as a Health Care issuer but does not describe its products, customers, or revenue model. Specific product lines, customer segments, and monetization details are not available in source data.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $11244.0M | $-308.0M | $-957.0M | N/A | $339.0M | $1966.0M | $6278.9M |
| FY 2024 | $10636.0M | $14.0M | $-649.0M | N/A | $540.4M | $1764.0M | $8441.1M |
| FY 2023 | $10360.0M | $707.0M | $2656.0M | N/A | $1259.8M | N/A | $2909.1M |
Per the SEC financials, revenue rose from $10360.0M in FY 2023 to $11244.0M in FY 2025, while operating income moved from $707.0M to $-308.0M and net income from $2656.0M to $-957.0M. Per the market data, gross margin is 30.1%, operating margin -2.7%, and net margin -8.5%. ROIC is -2.4%. Per the RQD rating, the Altman Z-Score is 2.22 and the Piotroski F-Score is 6/9, with Debt/Equity at 0.96. Reported debt fell from $8441.1M in FY 2024 to $6278.9M in FY 2025 while cash rose to $1966.0M, and FCF declined from $1259.8M in FY 2023 to $339.0M in FY 2025.
Recent Catalysts & News Wire Analysis
Six news items are tagged to BAX, each labeled YELLOW and as MARKET WIRE. Headlines reference the Vantive transition and margin recovery, a stock-down move, a valuation claim of being about 30% undervalued on cash flow, a technical breakout setup, and a lower trading move. The summaries are generic wire descriptions and do not contain figures, so the specifics of each catalyst are not available in source data. Risk watch items implied by the headlines are the Vantive transition complicating margin recovery and the day-level price declines. Per the Butterfly Supply-Chain Graph, there are no proprietary signals.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, supply chain status is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. The only sector context is the Health Care / Medical/Dental Instruments classification.
Open Questions
- What is the Vantive transition, and what specific margin effects does it carry, given that operating margin is -2.7%?
- Which institutional holders and insiders underlie the whale 13F and insider pillar scores of 10/20 and 12/20?
- What drove the decline from FY 2023 operating income of $707.0M to FY 2025 operating loss of $-308.0M, and is there a path to recovery?
- What are the P/E (TTM) and EV/EBITDA figures, which are absent from the source data?
- What products and customers generate the $11244.0M revenue base?
BAX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Baxter International Inc. (BAX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 10h ago
Baxter International Inc. (BAX) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Baxter International Inc. (BAX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 13h ago
Baxter International: The Vantive Transition Complicates Margin Recovery Seeking Alpha report covering Baxter International Inc. (BAX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 16h ago
Why Baxter (BAX) Stock Is Down Today TradingView report covering Baxter International Inc. (BAX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 19h ago
Baxter (BAX) Stock May Be 30% Undervalued On Cash Flow Yahoo Finance report covering Baxter International Inc. (BAX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ChartMill • 22h ago
Baxter International Inc (NYSE:BAX) Breakout Setup Shows Technical Strength ChartMill report covering Baxter International Inc. (BAX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
Why Is Baxter Stock Trading Lower on Thursday? Benzinga report covering Baxter International Inc. (BAX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE marketscreener.com • 1d ago
Earnings Flash (BAX) Baxter International Inc. Posts Q3 Adjusted EPS $0.58 per Share, vs. FactSet Est of $0.52 marketscreener.com report covering Baxter International Inc. (BAX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Baxter (BAX) Stock Price Slips Despite Q3 Results Backing Turnaround Simply Wall St report covering Baxter International Inc. (BAX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
BAX Bull vs. Bear Conversation Board — What's Your Call at $23.00?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BAX 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $25.38 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is BAX (D • RQD 51/100) a Buy at $23.50?
Welcome to the BAX (Baxter International Inc.) Roar Pit. Current RQD Composite is 51/100 (Roarable Sell — Underperform / Distribution Warning) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $17.86 (-24.0%)
Spot @ $23.50 Pump the brakes on BAX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on BAX, but look at what you are paying: current EV/EBITDA multiples with 30.1% gross margins. Unless Baxter International Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH
🎯 Target: $28.67 (+22.0%)
Spot @ $23.50 BAX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on BAX, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $23.50 (52-wk range $15.73 - $30.00), any beat on forward guidance forces shorts and underweight funds to chase.